Sol-Gel's rosacea drug clears late-stage hur­dle; uniQure's he­mo­phil­ia gene ther­a­py im­press­es with PhII da­ta

→ Is­rael’s Sol-Gel Tech­nolo­gies‘ mi­croen­cap­su­la­tion plat­form — de­signed to en­trap ac­tive in­gre­di­ents in porous sil­i­ca mi­cro­cap­sules to ad­dress the lim­i­ta­tions of top­i­cal drug de­liv­ery by sta­bi­liz­ing the in­gre­di­ents, ex­tend­ing drug de­liv­ery time and re­duc­ing po­ten­tial ir­ri­ta­tion — was val­i­dat­ed when its papu­lo­pus­tu­lar rosacea prod­uct made of mi­croen­cap­su­lat­ed ben­zoyl per­ox­ide, Ep­so­lay, cleared twin late-stage stud­ies. “While we ex­pect­ed to see strong ef­fi­ca­cy and tol­er­a­bil­i­ty with Ep­so­lay, the rapid ef­fi­ca­cy was a stand­out in our Phase 3 stud­ies,” said Alon Seri-Levy, Sol-Gel’s chief, in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER